Literature DB >> 24900751

Inhibitors of PI3Kβ as Potential Treatment for Cancer.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2013        PMID： 24900751      PMCID： PMC4027437          DOI： 10.1021/ml400274v

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  PI3 kinase inhibitors in the clinic: an update.

Authors:  Jean-Emmanuel Kurtz; Isabelle Ray-Coquard
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

2.  Beta-testing of PI3-kinase inhibitors: is beta better?

Authors:  Peter R Shepherd; William A Denny
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

Review 3.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.